Klotho Neurosciences, Inc.

KLTO

NASDAQ

Healthcare

Biotechnology

Omaha, NE, US3 employeesklothoneuro.com

$0.38

-0.03(-7.10%)

Mkt Cap $20M

$0.13

$2.01

52-Week Range

At a Glance

AI-generated

Klotho Neurosciences reported a wider operating and net loss in FY2025, reflecting continued investment in its pre-revenue pipeline and public company infrastructure, with cash burn accelerating as expected during development.

8-K

Greenland Mines, Ltd received written notification from Nasdaq on March 19, 2026, granting a six-month extension until September 14, 2026, to regain compliance with the Bid Price Rule requiring a $1.00 minimum bid price for 10 consecutive business days. The Company meets all other applicable Nasdaq listing requirements, but failure to comply risks delisting of its common stock.

$20M

Market Cap

—

Revenue

—

Net Income

Employees3

Fundamentals

How The Business Makes Money

Klotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. The company is based in Omaha, Nebraska.

Industry Biotechnology

Activity

What Changed Recently

Securities Issuance

Mar 1, 2026

. Unregistered Sales of Equity Securities On March 2, 2026, Klotho Neurosciences, Inc. (the “Company”) closed and completed the private placement (the “Financin

Material Agreement

Feb 23, 2026

. Entry Into or Amendment of a Material Definitive Agreement. On February 19, 2026, Klotho Neurosciences, Inc. (the “Company”) entered into a Securities Purchas

Regulation FD

Mar 22, 2026

and Exhibit 99.1, attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended and shall not be de

Regulation FD

Mar 11, 2026

and Exhibit 99.1 shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1

Asset Acquisition+4 More

Mar 9, 2026

Entry into Material Agreement On March 4, 2026, Klotho Neurosciences, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”)

Peer Companies

Company	Price	Change	Market Cap	P/E
NRXSNeurAxis, Inc.	$7.21	+0.42%	$81M	-8.5
RLYBRallybio Corporation	$8.38	-0.24%	$44M	-5.4
NERVMinerva Neurosciences, In...	$5.27	-5.89%	$37M	-0.2
IBIOiBio, Inc.	$1.97	+0.77%	$31M	-8.9
XCURExicure, Inc.	$4.22	+0.96%	$27M	-3.0
NRSNNeuroSense Therapeutics L...	$0.83	+9.22%	$20M	-2.2
TAOXTAO Synergies Inc.	$5.74	+0.20%	$20M	-0.6
CVKDCadrenal Therapeutics, In...	$4.75	-3.06%	$11M	-0.9

Company Profile

CIK0001907223

ISINUS49876K1034

Phone833 931 6330

Address13576 Walnut Street, Omaha, NE, 68144, US

SEC EDGAR